WO2010136847A1 - Coated metformin with pioglitazone solution - Google Patents

Coated metformin with pioglitazone solution Download PDF

Info

Publication number
WO2010136847A1
WO2010136847A1 PCT/IB2009/052200 IB2009052200W WO2010136847A1 WO 2010136847 A1 WO2010136847 A1 WO 2010136847A1 IB 2009052200 W IB2009052200 W IB 2009052200W WO 2010136847 A1 WO2010136847 A1 WO 2010136847A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
mixtures
solution
agent
insulin sensitizer
Prior art date
Application number
PCT/IB2009/052200
Other languages
French (fr)
Inventor
Farhad Farshi
Recep Avci
Hasan Samuk
Serdar Soylemez
Fikret Koc
Erhan Koc
Original Assignee
Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority to PCT/IB2009/052200 priority Critical patent/WO2010136847A1/en
Publication of WO2010136847A1 publication Critical patent/WO2010136847A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Abstract

The present invention relates to coating of biguanide antihyperglycaemic agents (such as metformin hydrochloride) with solution of insulin sensitizers (such as thiazolidinediones; pi- oglitazone hydrochloride).

Description

Description

Title of Invention: COATED METFORMIN WITH PI- OGLITAZONE SOLUTION

[1] The present invention relates to coating of biguanide antihyperglycaemic agents

(such as metforminhydrochloride)with solution of insulin sensitizers (such as thiazo- lidinediones ; pioglitazone hydrochloride).

[2] Metformin / Pioglitazone combination product saled under the brand name

Compectact™ is prepared by separate granulation of pioglitazone and metformin and tabletting thereof.

[3] Since the ratio of Metformin / Pioglitazone differs as 850mg /15 mg homogeneity problem may arise . This is especially the case when the particle size of actives and ex- cipients differs considerably. Another impact on dissolution is the very spare solubility of Pioglitazone HCl especially as crystalline particles.

[4] To solve above mentioned technical problems coating of metformin with pioglitazone solution approach is applied oursides. But this is not an easy task since pioglitazone HCl is insoluble in many pharmaceutically suitable solvents and if soluble vast amounts of solvent is needed for this purpose, which is not suitable for coating purposes.Trying some organic solvents showed none of them has enough completely dissolving capacity. After a series of trial and evaluation of the aspects we invented that using an acid is very helpful to diminish solvent amounts used to dissolve Pioglitazone HCl. We further found that adding water to organic solvent acid mixture further diminishes total amount of solvent used to dissolve Pioglitazone. Preferably Pioglitazone HCl is dissolved in a water miscible organic solvent / water/ acid mixture. More preferably Pioglitazone HCl is dissolved in Ethanol /water /diluted HCl in suitable proportions of the participant solvents to achieve a clear solution with suitable amount of total solvent used. Using less solvent amount is important due to shortening coat spraying times, saving solvent and such economical reasons. Using vast amounts of solvent would have also an effect on the dissolution and tabletting properties of the composition since Metformin HCl is fairly soluble in most organic solvents and water which would affect the consistency.

[5] The presence of phenyl ether and thiazolidinone groups in the molecule alleviate solution by adding further acid.

[6] EP 0 861 666 discloses that excipients are added to the active component or components and the resulting composition is compressed. Where necessary, the compressed product is coated, by the per se known technique, for masking the taste or for enteric dissolution or sustained release ( page 2, 0020) . EP 0 861 666 does not disclose that coating of metformin with pioglitazone hydrochloride solution.

[7] EP 1 231 918 claims a pharmaceutical composition characterized by thiazo- lidinedione and metformin hydrochloride are each dispersed within its own pharmaceutically acceptable carrier in the pharmaceutical composition. EP 1 231 918 points out that polyvinyl pyrollidone (or PVP) is particularly effective as a binder for use with metformin hydrochloride. However use of PVP informulations of pioglitazone destabilizes pioglitazone and impacts on stability. Therefore EP 1 231 918 delinetaes pioglitazone and metformin hydrochloride are each dispersed within its own pharmaceutically acceptable carrier in the pharmaceutical composition. EP 1 231 918 does not disclose coating of metformin with pioglitazone hydrochloride solution.

[8] EP 1 552 832 discloses a preparation coated with pioglitazone hydrochloride so as to obtain proper dissolution property of pioglitazone hydrochloride . In EP 1 552 832 , it is described that coating of metformin tablets with pioglitazone hydrochloride which is in dispersion form. All of the examples and claims explain coating of metfomin tablets with pioglitazone hydrochloride. It is not disclosed that coating of metformin with pioglitazone hydrochloride solution. In example 1, polyvinylpyrrolidone , polyethylene glycol 6000 and pioglitazone hydrochloride were dispersed in ethanol to give a coating solution (page 8, line 25). However it is only a dispersion process, there is no dissolving of pioglitazone namely it is not a solution since pioglitazone hydrochloride is not dissolved alone in ethanol. Thus process of EP 1 552 832 is only relevant to dispersions not dissolving.

[9] There is a need different approach from the prior art to create pharmaceutical compositions of pioglitazone and metformin.

[10] One aspect of this invention is coating of biguanide antihyperglycaemic agent with thiazolidinedione solution. Thiazolidinedione may be pioglitazone or its salts (preferable hydrochloride), rosiglitazone or its salt (preferable maleate) or any other thiazolidinedione.Biguanides may be phenformin, metformin, buformin, or a salt thereof (e.g., hydrochloride, fumarate, succinate) etc. Preferredbiguanide is metformin or a salt thereof (preferably metformin hydrochloride). Pharmaceutical formulations and combinations may contain further active ingredients along with them.

[11] Pioglitazone hydrochloride solution comprising ;

[12] (i) an inorganic acid or mixtures of inorganic acids or,

[13] (ii)anorganicacidor mixtures of organic acids or,

[14] (iii) mixtures of organic acids and inorganic acids or,

[15] (iv) mixture of an organic acid and an inorganic acid .

[16] - an organic solvent or mixtures of organic solventsand

[17] - optionally de-ionized water and,

[18] - optionally binder or binders. [19] Pioglitazone hydrochloride solution may further include suitable excipients. The character of the solution isinsulin sensitizer is completelydissolved.

[20] Organic solvents, used in preparation of solution are ,but not limited to, alcohols such as methanol, ethanol, propyl alcohol, isopropyl alcohol, 2-methyl-l-propanol etc. ; ketones such as acetone, methyl ethyl ketone, methyl isobutyl ketone etc. ; esters such as methyl acetate, ethyl acetate, propyl acetate, isopropyl acetate, ethyl formate etc. ; hydrocarbons such as heptane ; halogenated hydrocarbons such as dichloromethane. The organic solvent is preferably an alcohol and more preferably methanol, ethyl alcohol, propyl alcohol, isopropyl alcohol and the so on. Ethyl alcohol is mostly preferred. Organic solvents can be used alone or in combination with water.

[21] Preferable examples of organic acids are formic acid, acetic acid, fumaric acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, p- toluenesulfonic acid .

[22] Preferable examples of inorganic acid is hydrochloric acid which is in the form of solution in water.

[23] Mixtures of organic solvents may also be used. Using of mixtures of organic solvents can be in an appropriate ratio. Mixtures may contain water.

[24] The percentages pioglitazone / water / organic solvent / hydrochloric acideis critical due to poor solubility of pioglitazon hydrochloride and need for low solution amount. The solution comprising insulin sensitizer is in the range of from 0.01 % to 9.00 % , water is in the range of from 00.00 % to 70 %, organic solvent or mixtures of organic solvents are in the range of from 20 % to 75 %, acid or mixtures of acids are in the range of from 0.05 % to 50 % by weight, binder or mixtures of binders are are in the range of from 5 % to 35.

[25] Weight of acid is based on real amount of said acid.

[26] The binder, which is used in preparation solution, may be, but not limited to, starch, polyethyleneglycol, microcrystalline cellulose, hydroxypropyl cellulose, hydrox- ypropylmethyl cellulose,carboxymethylcellulose, sodium alginate,ethylcellulose, polyvinylpyrrolidone, pregelatinized starch, gelatin or mixtures thereof. Preferred binder is polyethyleneglycol or povidone or mixtures thereof .

[27] The solution can also be prepared without binder or mixtures of binders.

[28] It is important to completely dissolve Pioglitazon HCl in the granulation solution to surround the metformin hydrochloride particles.

[29] The pioglitazone hydrochloride solution of the present invention may contain further excipient or excipients.

[30] This invention describes coating particles of biguanide antihyperglycaemic agent with thiazolidinedione solution. On the other hand this invention embraces every kind of particles which include particles of biguanide antihyperglycaemic agent. It means that direct compression (DC) forms of biguanide antihyperglycaemic agent may also be used. DC forms are available on the market. In case of using DC forms of biguanide antihyperglycaemic agent , biguanide antihyperglycaemic agent particles adhere to other excipient or excipients. Of course, instead of receiving DC forms , biguanide antihyperglycaemic agent may be granulated with suitable excipient or excipients and then thiazolidinedione solution coating may be administered according to this invention .Particles of biguanide antihyperglycaemic agent alone may also be coated . Coexisting particles ,whatsoever, of biguanide antihyperglycaemic agent with other excipient or excipients can be coated according to this invention. Compressed dosage forms of biguanide antihyperglycaemicagent or pellets and dosage forms prepared by using this pellets of biguanide antihyperglycaemic agent can also becoated.

[31] In another aspect this invention embraces a method of coating of biguanide particles with thiazolidinedione solution.

[32] Method of coating has following steps ;

[33] (a) Ethyl alcohol, de-ionized water and hydrochloric acid are mixed in a solution tank.

[34] (b) Polyethyleneglycol or povidone or any other selected binder or mixtures thereof may be added to the solvent mixture slowly by continuous stirring.

[35] (c) The solution is mixed and checked for completely dissolving and if not continued to stir.

[36] (d) Pioglitazon Hydrochloride is added to solution and mixed . The solution checked for completely dissolving and if not continued to stir.

[37] (e) Metformin Hydrochloride is layed on the bed.

[38] (f)The prepared solution of Pioglitazon Hydrochloride is sprayed onto the Metformin

Hydrochloride particles in fluid bed or any other suitable vehicle .

[39] Steps set out above from a to f are called as Phase A in subjacent sections of this application.

[40] The present inventors have also invented that pharmaceutical formulation includes coating of metformin particles with pioglitazone hydrochloride solution shows same or identical and suitable dissolution properties when compared to reference (Competact™) product .

[41] According to this invention, pharmaceutical formulation exhibits a dissolution profile which has similarity factor (f2) of at least 50 to 100 in dissolution environments when compared to the reference (Competact ™ ) dissolution profile. Preferred dissolution mediums are 0.1 NHCI, pH 2.5, pH 4.5 and pH 6.8 . Dissolution tests are performed by a USP Method II - Paddle method at 370C, 50 rpm,900 ml. As an exemplary dissolution profile in pH 2.5 medium is given (Figure 1).

[42] Another aspect of this invention is to provide pharmaceutical formulations. Pharma- ceutical formulations may be in the form of such as tablet, bilayer or trilayer tablet, caplet, capsule, granule, powder etc. These forms may be a controlled release, immediately release , sustained release, modified release and the like. Formulations may include excipients as disintegrants, binders, lubricants, coloring agents, pH regulators, surfactants, stabilizers, flavours, coating agents and the like . Pharmaceutical formulations should contain both at least a biguanide antihyperglycaemic agent and at least a thiazolidinedione agent. Further active pharmaceutical ingredient may be present in formulations and combinations.

[43] Disintegrants are such as but not limited to carboxymethyl cellulose, calcium car- boxymethyl cellulose, sodium carboxymethyl starch, modified starches, sodium starch glycolate, croscarmellose sodium, crospovidone, hydroxypropyl cellulose et. Preferred disintegrant is croscarmellose sodium.

[44] Binders are such as but not limited to starch, microcrystalline cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, sodium alginate,ethylcellulose, polyvinylpyrrolidone, pregelatinized starch, gelatin or mixtures thereof, etc. Preferred binder is microcrystalline Cellulose .

[45] Fillers are lactose, microcrystalline cellulose, silicified microcrystalline cellulose, powdered cellulose, calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, sucrose, glucose, dextrates, dextrins, dextrose, fructose, lactitol, mannitol, sorbitol, starch or mixtures thereof. Preferred filler is lactose.

[46] Lubricants are magnesium stearate, magnesium lauryl sulphate,sodium stearyl fumarate, polyethylene glycol, stearic acid, colloidal silicon dioxide or mixtures thereof. Preferred lubricant is magnesium stearate

[47] The coating agent that can be used includes, for instance, ethylcellulose, hydrox- ymethylcellulose, polyethylene glycol, cellulose acetate phthalate, hydroxypropyl- methylcellulose phthalate, and Eudragit. Coating may further contain an excipient, for example, titanium oxide, talc, ferric oxide and the like. As a coating agent multifunction ingredient such as Opadry ® White YS-1R-7002 can also be used.

[48] In yet another aspect of this invention is to provide a preparation method of pharmaceutical formulation. The preparation of pharmaceutical formulation's steps are called as Phase B in this application. Phase B has following steps ;

[49] (a) Obtained granules from phase A are dried.

[50] (b) The prepared granules are sieved and blended with extra- granular excipients; such as lactose, microcrystalline cellulose and croscarmellose sodium.

[51] (c)The blended powder is lubricated by magnesium stearate or such excipients and compressed

[52] (d) Core tablets are coated with a suspension of Opadry ® white YS-lR-7002in de- ionized water. [53] (e) Film coated tablets are packaged.

[54] According to this invention, generally, in pharmaceutical formulations, metformin hydrochloride is from 70 to 90 %, pioglitazone hydrochloride is from 1 to 5 % , binder is from 5 to 15 %, filler is from 1 to 5 %, disintegrant is from 2 to 10 %, lubricant is from 0,1 to 5 %, coating agent is from 0.5 to 5 % by the total weight of the pharmaceutical formulation.

Claims

Claims
[Claim 1] A pharmaceutical composition includesat least both a biguanide antihy- perglycaemic agent and an insulin sensitizer characterized in that; (i) particles of biguanide antihyperglycaemic agent or (ii) granulated particles of biguanide antihyperglycaemic agent with an excipient or excipients or
(iii) ready for direct compression particles of biguanide antihyperglycaemic agent or
(iv) coexisting particles of biguanide antihyperglycaemic agent with other excipient or excipients or
(v)compressed dosage forms of biguanide antihyperglycaemic agent or (vi) pellets and dosage forms prepared by using this pellets of biguanide antihyperglycaemic agent are coated with insulin sensitizer solutionwherein insulin sensitizer is completely dissolved.
[Claim 2] As claimed in claim 1, insulin sensitizer solution comprising;
(a) an insulin sensitizer and
(b) an acid or mixtures of acids
(c) an organic solvent or mixtures of organic solvents and,
(d) optionally water and
(e) optionally a binder or mixtures of binders.
[Claim 3] As claimed in claim 2, the solution comprising insulin sensitizer is in the range of from 0.01 % to 9.00 % , water is in the range of from 00.00 % to 70 %, organic solvent or mixtures of organic solvents are in the range of from 20 % to 75 %, acid or mixtures of acids are in the range of from 0.05 % to 50 % by weight, binder or mixtures of binders are are in the range of from 5 % to 35.
[Claim 4] As claimed in claim 3, weight of acid is based on real amount. [Claim 5] As claimed in claim 2, organic solvent is selected from group consisting of methanol, ethanol, propyl alcohol, isopropyl alcohol, 2-methyl-l-propanol, acetone, methyl ethyl ketone, methyl isobutyl ketone, methyl acetate, ethyl acetate, propyl acetate, isopropyl acetate, ethyl formate, heptane, dichloromethane or mixtures thereof.
[Claim 6] As claimed in claim 2, an acid or mixtures of acids are (i) an inorganic acid or mixtures of inorganic acids or, (ii) an organic acid or mixtures of organic acids or, (iii) mixtures oforganic acids and inorganic acids or, (iv) mixture of an organic acid and an inorganic acid .
[Claim 7] As claimed in claim 6, organic acid is selected from group consisting of formic acid, acetic acid, fumaric acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, p-toluenesulfonic acid or mixtures thereof.
[Claim 8] As claimed in claim 6, inorganic acid is hydrochloric acid solution. [Claim 9] As claimed in claim 1, insulin sensitizer is thiazolidinedione [Claim 10] As claimed in claim 9, thiazolidinedione is pioglitazone hydrochloride. [Claim 11] As claimed in claim 1, biguanide antihyperglycaemic agent is metformin or its salts
[Claim 12] As claimed in claim 11, metformin is metformin hydrochloride [Claim 13] As claimed in claim 2 ,binder is selected from group consisting of starch, polyethyleneglycol, microcrystalline cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose,carboxymethylcellulose, sodium alginate,ethylcellulose, polyvinylpyrrolidone, pregelatinized starch, gelatin or mixtures thereof.
[Claim 14] As claimed in claim 1, to obtain a pharmaceutical composition , a preparation method of coating having steps of ;
(a) organic solvent or mixtures of organic solvents, de-ionized water and acid or mixtures of acids are mixed .
(b) binder or mixtures of binders are added to the solvent mixture slowly by continuous stirring.
(c) the solution is mixed and checked for completely dissolving
(d) insulin sensitizer is added to solution and mixed until completely dissolving
(e) biguanide antihyperglycaemic agent is layed on the bed
(f) the prepared solution of insulin sensitizer is sprayed onto the particles of biguanide antihyperglycaemic agent .
[Claim 15] As claimed in claim 1, pharmaceutical formulation is prepared by a method having following steps ;
(a) obtained granules from phase said in claim 14 are dried.
(b) the prepared granules are sieved and blended with extra-granular excipients
(c)the blended powder is lubricated and compressed by a tabletting machine.
(d) core tablets are coated with a suspension of film coating agent (Opadry ®) in de-ionized water.
(e) film coated tablets are packaged. [Claim 16] As claimed in claim 1, pharmaceutical composition comprising ;
(a) at least both a biguanide antihyperglycaemic agent and at least an insulin sensitizer and
(b) disintegrant or disintegrants and (c)binder or binders and
(d) filler or fillers and
(e) lubricant or lubricants and
(f) film coating agent or film coating agents
[Claim 17] As claimed in claim 16 , film coating agent is Opadry ® White YS- 1R-7002 [Claim 18] As claimed in claim 16, pharmaceutical formulation comprising metformin hydrochloride is from 70 to 90 %, pioglitazone hydrochloride is from 1 to 5 % , binder is from 5 to 15 %, filler is from 1 to 5 %, disintegrant is from 2 to 10 %, lubricant is from 0,1 to 5 %, coating agent is from 0.5 to 5 % by the total weight of the pharmaceutical formulation.
[Claim 19] As claimed in claim 16, disintegrant is selected from group consisting of carboxymethyl cellulose, calcium carboxymethyl cellulose, sodium carboxymethyl starch, modified starches, sodium starch glycolate, croscarmellose sodium, crospovidone, hydroxypropyl cellulose or mixtures thereof.
[Claim 20] As claimed in claim 16, binder is selected from group consisting of starch, microcrystalline cellulose, hydroxypropyl cellulose, hydrox- ypropylmethyl cellulose, sodium alginate,ethylcellulose, polyvinylpyrrolidone, pregelatinized starch, gelatin or mixtures thereof
[Claim 21] As claimed in claim 16, filler is selected from group consisting of lactose, microcrystalline cellulose, silicified microcrystalline cellulose, powdered cellulose, calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, sucrose, glucose, dextrates, dextrins, dextrose, fructose, lactitol, mannitol, sorbitol, starch or mixtures thereof.
[Claim 22] As claimed in claim 16, lubricant is selected from group consisting of magnesium stearate, magnesium lauryl sulphate,sodium stearyl fumarate, polyethylene glycol, stearic acid, colloidal silicon dioxide or mixtures thereof .
[Claim 23] As claimed in claim 1, pharmaceutical formulation exhibits a dissolution profile which has similarity factor (f2) of at least 50 to 100 in dissolution environments when compared to the reference (Compectact
™ ) dissolution profile. [Claim 24] As claimed in claim 23, dissolution mediums are 0.1 NHCI, pH 2.5, pH
4.5 and pH 6.8 . [Claim 25] As claimed in claim 23 and 24, dissolution tests are performed by a
USP Method II - Paddle method at 370C, 50 rpm,900 ml.
PCT/IB2009/052200 2009-05-26 2009-05-26 Coated metformin with pioglitazone solution WO2010136847A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IB2009/052200 WO2010136847A1 (en) 2009-05-26 2009-05-26 Coated metformin with pioglitazone solution

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2009/052200 WO2010136847A1 (en) 2009-05-26 2009-05-26 Coated metformin with pioglitazone solution
TR2012/02048T TR201202048T2 (en) 2009-05-26 2009-05-26 metformin, pioglitazone coated with the solution.

Publications (1)

Publication Number Publication Date
WO2010136847A1 true WO2010136847A1 (en) 2010-12-02

Family

ID=41718464

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/052200 WO2010136847A1 (en) 2009-05-26 2009-05-26 Coated metformin with pioglitazone solution

Country Status (2)

Country Link
TR (1) TR201202048T2 (en)
WO (1) WO2010136847A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001035940A2 (en) * 1999-11-16 2001-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride
WO2001082875A2 (en) * 2000-05-01 2001-11-08 Aeropharm Technology, Inc. A core formulation
WO2003005991A1 (en) * 2001-07-10 2003-01-23 Aeropharm Technology Incorporated A core formulation
WO2004101561A1 (en) * 2003-05-13 2004-11-25 Synthon B.V. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001035940A2 (en) * 1999-11-16 2001-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride
WO2001082875A2 (en) * 2000-05-01 2001-11-08 Aeropharm Technology, Inc. A core formulation
WO2003005991A1 (en) * 2001-07-10 2003-01-23 Aeropharm Technology Incorporated A core formulation
WO2004101561A1 (en) * 2003-05-13 2004-11-25 Synthon B.V. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same

Also Published As

Publication number Publication date
TR201202048T2 (en) 2012-04-24

Similar Documents

Publication Publication Date Title
JP4901727B2 (en) Coated tablet formulation and methods
EP1232747B1 (en) Controlled release tablet of bupropion hydrochloride
AU2003264002B2 (en) Modified-release tablet of bupropion hydrochloride
US5807579A (en) Pseudoephedrine combination pharmaceutical compositions
CA2478558C (en) Naltrexone hydrochloride compositions
US20030113376A1 (en) Omeprazole formulation
US6610326B2 (en) Divalproex sodium tablets
US6174548B1 (en) Omeprazole formulation
US6515010B1 (en) Carvedilol methanesulfonate
CN1227004C (en) Partial fatty acid oxidation inhibitors in treatment of congestive heart failure
US20040028741A1 (en) Oral preparations with favorable disintegration characteristics
US9180101B2 (en) Pharmaceutical composition simultaneously having rapid-acting property and long-acting property
AU763309B2 (en) Bioenhanced formulations comprising eprosartan in oral solid dosage form
BG61796B1 (en) Orally applicable pantoprazol-containing medicamentous forms
JPWO2006070781A1 (en) Basic drug or matrix type sustained-release preparation and a production method thereof a salt thereof
US20040028735A1 (en) Pharmaceutical formulation
AU757915B2 (en) Controlled release bupropion formulation
US20100081685A1 (en) Pharmaceutical composition
US7427414B2 (en) Modified release oral dosage form using co-polymer of polyvinyl acetate
JP4718465B2 (en) Novel pharmaceutical formulations comprising biguanide and thiazolidinedione derivative
CN1635894A (en) Dosage form for treatment of diabetes mellitus
US6468560B2 (en) Controlled release dosage form of [R-(Z)]-α-(methoxyimino)-α-(1-azabicyclo[2.2.2]oct-3yl) acetonitrile monohydrochloride
US20090124702A1 (en) Pharmaceutical Compositions of Metformin
US20040028737A1 (en) Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
ES2523729T3 (en) A pharmaceutical composition comprising telmisartan and hydrochlorothiazide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09786406

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012/02048

Country of ref document: TR

122 Ep: pct application non-entry in european phase

Ref document number: 09786406

Country of ref document: EP

Kind code of ref document: A1